137 related articles for article (PubMed ID: 10071246)
1. Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence.
Day RM; Hao X; Ilyas M; Daszak P; Talbot IC; Forbes A
Virchows Arch; 1999 Feb; 434(2):121-5. PubMed ID: 10071246
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies.
Mitselou A; Ioachim E; Peschos D; Charalabopoulos K; Michael M; Agnantis NJ; Vougiouklakis T
Exp Oncol; 2007 Mar; 29(1):54-60. PubMed ID: 17431390
[TBL] [Abstract][Full Text] [Related]
3. Changes in E-cadherin immunoreactivity in the adenoma-carcinoma sequence of the large bowel.
Gagliardi G; Kandemir O; Liu D; Guida M; Benvestito S; Ruers TG; Benjamin IS; Northover JM; Stamp GW; Talbot IC
Virchows Arch; 1995; 426(2):149-54. PubMed ID: 7757285
[TBL] [Abstract][Full Text] [Related]
4. Syndecan-1, Epithelial-Mesenchymal Transition Markers (E-cadherin/β-catenin) and Neoangiogenesis-related Proteins (PCAM-1 and Endoglin) in Colorectal Cancer.
Mitselou A; Galani V; Skoufi U; Arvanitis DL; Lampri E; Ioachim E
Anticancer Res; 2016 May; 36(5):2271-80. PubMed ID: 27127133
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical study of syndecan-1 down-regulation and the expression of p53 protein or Ki-67 antigen in oral leukoplakia with or without epithelial dysplasia.
Kurokawa H; Matsumoto S; Murata T; Yamashita Y; Tomoyose T; Zhang M; Fukuyama H; Takahashi T
J Oral Pathol Med; 2003 Oct; 32(9):513-21. PubMed ID: 12969225
[TBL] [Abstract][Full Text] [Related]
6. The expression of syndecan-1 is preferentially reduced compared with that of E-cadherin in acantholytic squamous cell carcinoma.
Bayer-Garner IB; Smoller BR
J Cutan Pathol; 2001 Feb; 28(2):83-9. PubMed ID: 11168756
[TBL] [Abstract][Full Text] [Related]
7. An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1.
Pap Z; Pávai Z; Dénes L; Kovalszky I; Jung J
Pathol Oncol Res; 2009 Dec; 15(4):579-87. PubMed ID: 19253033
[TBL] [Abstract][Full Text] [Related]
8. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells.
Kato M; Saunders S; Nguyen H; Bernfield M
Mol Biol Cell; 1995 May; 6(5):559-76. PubMed ID: 7545031
[TBL] [Abstract][Full Text] [Related]
9. Syndecan-1 expression in mammary epithelial tumor cells is E-cadherin-dependent.
Leppä S; Vleminckx K; Van Roy F; Jalkanen M
J Cell Sci; 1996 Jun; 109 ( Pt 6)():1393-403. PubMed ID: 8799827
[TBL] [Abstract][Full Text] [Related]
10. [The expression of cell adhesion molecule Syndecan-1 and E-candherin in laryngeal cancer].
Li Y; Yang C
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2003 Dec; 17(12):736-8. PubMed ID: 15017723
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous loss of expression of syndecan-1 and E-cadherin in the embryonic palate during epithelial-mesenchymal transformation.
Sun D; Mcalmon KR; Davies JA; Bernfield M; Hay ED
Int J Dev Biol; 1998 Jul; 42(5):733-6. PubMed ID: 9712528
[TBL] [Abstract][Full Text] [Related]
12. Reduction of syndecan-1 expression in differentiated type early gastric cancer and background mucosa with gastric cellular phenotype.
Watari J; Saitoh Y; Fujiya M; Shibata N; Tanabe H; Inaba Y; Okamoto K; Maemoto A; Ohta T; Yasuda A; Ayabe T; Ashida T; Yokota K; Obara T; Kohgo Y
J Gastroenterol; 2004; 39(2):104-12. PubMed ID: 15069616
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of syndecan-1 expression in breast cancer.
Leivonen M; Lundin J; Nordling S; von Boguslawski K; Haglund C
Oncology; 2004; 67(1):11-8. PubMed ID: 15459490
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression of molecules of the cadherin/catenin complex in the transition from colorectal adenoma to carcinoma.
Hao X; Palazzo JP; Ilyas M; Tomlinson I; Talbot IC
Anticancer Res; 1997; 17(3C):2241-7. PubMed ID: 9216695
[TBL] [Abstract][Full Text] [Related]
15. Heparan sulphate proteoglycan expression in human primary liver tumours.
Roskams T; De Vos R; David G; Van Damme B; Desmet V
J Pathol; 1998 Jul; 185(3):290-7. PubMed ID: 9771483
[TBL] [Abstract][Full Text] [Related]
16. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
Mikami S; Ohashi K; Usui Y; Nemoto T; Katsube K; Yanagishita M; Nakajima M; Nakamura K; Koike M
Jpn J Cancer Res; 2001 Oct; 92(10):1062-73. PubMed ID: 11676857
[TBL] [Abstract][Full Text] [Related]
17. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
[TBL] [Abstract][Full Text] [Related]
18. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck.
Inki P; Joensuu H; Grénman R; Klemi P; Jalkanen M
Br J Cancer; 1994 Aug; 70(2):319-23. PubMed ID: 8054282
[TBL] [Abstract][Full Text] [Related]
19. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer.
Contreras HR; Ledezma RA; Vergara J; Cifuentes F; Barra C; Cabello P; Gallegos I; Morales B; Huidobro C; Castellón EA
Urol Oncol; 2010; 28(5):534-40. PubMed ID: 19450993
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer.
Fujiya M; Watari J; Ashida T; Honda M; Tanabe H; Fujiki T; Saitoh Y; Kohgo Y
Jpn J Cancer Res; 2001 Oct; 92(10):1074-81. PubMed ID: 11676858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
